ATE323496T1 - Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren - Google Patents

Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren

Info

Publication number
ATE323496T1
ATE323496T1 AT95940581T AT95940581T ATE323496T1 AT E323496 T1 ATE323496 T1 AT E323496T1 AT 95940581 T AT95940581 T AT 95940581T AT 95940581 T AT95940581 T AT 95940581T AT E323496 T1 ATE323496 T1 AT E323496T1
Authority
AT
Austria
Prior art keywords
antigen
host
tumor
medication
tumors
Prior art date
Application number
AT95940581T
Other languages
English (en)
Inventor
Dennis A Carson
Eyal Raz
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23306377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323496(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE323496T1 publication Critical patent/ATE323496T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
AT95940581T 1994-11-03 1995-11-01 Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren ATE323496T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/334,260 US5679647A (en) 1993-08-26 1994-11-03 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides

Publications (1)

Publication Number Publication Date
ATE323496T1 true ATE323496T1 (de) 2006-05-15

Family

ID=23306377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940581T ATE323496T1 (de) 1994-11-03 1995-11-01 Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren

Country Status (8)

Country Link
US (1) US5679647A (de)
EP (1) EP0789574B1 (de)
JP (1) JPH10509702A (de)
AT (1) ATE323496T1 (de)
AU (1) AU4198196A (de)
CA (1) CA2203991C (de)
DE (1) DE69534946T2 (de)
WO (1) WO1996014074A1 (de)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6348449B1 (en) 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
EP1860192A1 (de) * 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US20020164318A1 (en) * 1997-02-18 2002-11-07 Houghton Alan N. Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
CZ299638B6 (cs) 1997-06-30 2008-10-01 Rhone-Poulenc Rorer S. A. Lécivo pro genovou terapii, které se vnáší do nádoru za aplikace slabého elektrického pole, a kombinovaný produkt pro genovou terapii
KR20010020571A (ko) 1997-06-30 2001-03-15 자끄 사비나 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
KR20080009171A (ko) * 1997-08-13 2008-01-24 더 유에이비 리서치 파운데이션 유전자 벡터의 국소 적용에 의한 백신접종
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US6432641B1 (en) 1997-12-16 2002-08-13 University Of Saskatchewan Technologies Inc. Conductive metal-containing nucleic acids
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
EP1849477A1 (de) * 1998-02-25 2007-10-31 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Mitteln zur Verbesserung der Hautpenetration und schrankenbrechenden Mitteln zur Verbesserung der transkutanen Immunantwort
ATE247979T1 (de) * 1998-02-25 2003-09-15 Us Gov Sec Army Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der durch adp- ribosylating-exotoxin induzierten immunantwort
EP1356823B1 (de) * 1998-02-25 2013-01-02 THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der durch ein Adjuvant induzierten Immunantwort
AU759765B2 (en) * 1998-03-20 2003-05-01 Genzyme Corporation Compositions and methods for antigen-specific vaccination
CN1629185B (zh) 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
AU4078599A (en) 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7851591B1 (en) 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
EP1165132B1 (de) 1999-04-08 2011-10-19 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU4981900A (en) * 1999-05-03 2000-11-17 Uab Research Foundation, The Noninvasive genetic immunization, expression products therefrom, and uses thereof
BR0010322A (pt) 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
US20020151515A1 (en) * 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
ATE482233T1 (de) * 1999-06-28 2010-10-15 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US7015204B1 (en) * 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
EP1842549A3 (de) 1999-12-28 2007-10-17 Pharmexa Inc. Optimierte Minigene und mit diesen kodierte Peptide
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
CA2401327C (en) * 2000-03-03 2014-05-06 Valentis, Inc. Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
EP1278541A1 (de) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Verbesserung der immunogenität bei der verwendung einer kombination von dns und vacciniavirus-vektor impfstoffen
NZ521715A (en) * 2000-04-28 2008-01-31 Mannkind Corp Method of identifying and producing antigen peptides and use thereof as vaccines
US7851212B2 (en) * 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6595947B1 (en) 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
PT1296714E (pt) 2000-06-22 2009-10-15 Coley Pharm Gmbh Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro
AU2002218786A1 (en) 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
CA2425648A1 (en) 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
JP4194365B2 (ja) * 2000-10-31 2008-12-10 エムジーアイ ファーマ バイオロジックス インコーポレイテッド Ｃｙｐ１ｂ１核酸および使用の方法
US7393921B2 (en) * 2000-12-04 2008-07-01 Institute For Systems Biology Prostate-specific polypeptide pamp and encoding nucleic acid molecules
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20020142337A1 (en) * 2001-03-29 2002-10-03 Edwards David N. Hybrid gene libraries and uses thereof
CA2439111A1 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US20020175317A1 (en) * 2001-05-24 2002-11-28 Lee Jeremy Stuart Nucleic acid circuit elements and methods
ATE336276T1 (de) 2001-06-08 2006-09-15 Becton Dickinson Co Vorrichtung zur manipulation von nadeln oder polierarray
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003015615A2 (en) 2001-08-15 2003-02-27 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
AU2002365144A1 (en) * 2001-10-29 2003-06-30 Becton, Dickinson And Company Method and device for the delivery of a substance
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US20030224392A1 (en) * 2002-01-28 2003-12-04 Manuel Engelhorn Method for identification of mutant antigens with enhanced immunogenicity
WO2004041997A2 (en) * 2002-05-01 2004-05-21 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
EP1504029A2 (de) * 2002-05-06 2005-02-09 University of British Columbia Expressionssystem für grosse funktionelle proteine
CA2385110A1 (en) * 2002-05-06 2003-11-06 University Of British Columbia Co-expression system for large functional proteins
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2497103C (en) 2002-08-29 2011-07-19 Becton, Dickinson And Company Microabrader with controlled abrasion features
DE60332377D1 (de) * 2002-10-21 2010-06-10 Eisai Inc Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
US20040223949A1 (en) * 2002-10-22 2004-11-11 Sunnybrook And Women's College Health Sciences Center Aventis Pasteur, Ltd. Vaccines using high-dose cytokines
EP1565200A4 (de) 2002-11-27 2009-06-24 Agensys Inc NUKLEINSûURE ENTSPRECHENDES PROTEIN 24P4C12 ZUR BEHANDLUNG UND ERKENNUNG VON KREBS
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
JP2007524361A (ja) 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 膀胱癌及びその他の癌の治療及び検出に有用な名称１５８ｐ１ｄ７の核酸及び対応タンパク質
US20040235019A1 (en) * 2003-03-06 2004-11-25 Agouron Pharmaceuticals, Inc. Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
WO2004098497A2 (en) * 2003-04-28 2004-11-18 Genencor International, Inc. Cd4+ human papillomavirus (hpv) epitopes
CN101090729B (zh) 2003-05-30 2014-07-23 艾更斯司股份有限公司 前列腺干细胞抗原(psca)变体及其序列
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
WO2004112825A2 (en) * 2003-06-17 2004-12-29 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
CN1846000B (zh) * 2003-09-05 2012-10-03 金克克国际有限公司 Hpv cd8+t细胞表位
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
BRPI0509788A (pt) * 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
PL1753871T3 (pl) 2004-05-28 2016-01-29 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA)
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7316665B2 (en) 2004-08-25 2008-01-08 Becton, Dickinson And Company Method and device for the delivery of a substance including a covering
WO2006071934A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1835932A2 (de) * 2004-12-29 2007-09-26 Mannkind Corporation Verfahren zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
JP2008538894A (ja) * 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
WO2006091722A2 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2325305B1 (de) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptid-Impfstoff für Lungenkrebs, der TTK, URLC10 oder KOC1 Polypeptide exprimiert
PT1855707E (pt) 2005-02-28 2012-05-25 Oncotherapy Science Inc Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos
CA2600036A1 (en) * 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
EP2385060A3 (de) 2005-06-17 2012-02-15 Mannkind Corporation Verfahren und Zusammensetzungen zum Auslösen von multivalenten Immunreaktionen gegen auf Krebszellen und Tumor-Stroma exprimierte dominante und subdominante Epitope
KR101325194B1 (ko) 2005-07-27 2013-11-06 온코세라피 사이언스 가부시키가이샤 대장암 관련 유전자 ｔｏｍ３４
JP2009505979A (ja) * 2005-08-10 2009-02-12 オクラホマ メディカル リサーチ ファンデーション アルツハイマー病の治療に使用するためのトランケート型メマプシン２
EP1948139A4 (de) * 2005-11-18 2012-04-04 3M Innovative Properties Co Überziehbare zusammensetzungen, daraus erhaltene überzüge und mikroanordnungen mit diesen überzügen
EP1962942A1 (de) * 2005-12-21 2008-09-03 3M Innovative Properties Company Mikronadelvorrichtungen
EP2476697B1 (de) 2006-10-17 2015-06-17 Oncotherapy Science, Inc. Peptidvakzinen für MPHOSPH1-Polypeptide exprimierenden Krebs
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
CN101861162A (zh) * 2007-03-14 2010-10-13 高世英 通过粘膜给予白介素治疗癌症的方法
TWI434853B (zh) 2007-04-11 2014-04-21 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
WO2009059011A2 (en) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2288379A4 (de) 2008-05-19 2012-08-08 Advaxis Doppeltes freisetzungssystem für heterologe antigene
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2329044B1 (de) 2008-08-27 2016-05-18 Oncotherapy Science, Inc. Prmt1 für zielgene zur krebstherapie und -diagnose
US8784829B2 (en) * 2008-10-23 2014-07-22 Intervet Inc. Lawsonia intracellularis vaccines
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP3115063A3 (de) 2008-12-03 2017-04-19 The John Hopkins University Galektin-3 und annexin a2 als immunologisches zielmolekül
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
JP5711149B2 (ja) 2009-01-13 2015-04-30 ステムバイオス テクノロジーズ，インコーポレイテッド 非胚性幹細胞およびその使用
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
WO2010106770A1 (en) 2009-03-18 2010-09-23 Oncotherapy Science, Inc. Neil3 peptides and vaccines including the same
CN102459576B (zh) 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
RU2570560C2 (ru) 2010-03-11 2015-12-10 Онкотерапи Сайенс, Инк. Пептиды hjurp и содержащие их вакцины
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
TWI635177B (zh) 2010-08-04 2018-09-11 幹細胞生物科技公司 體幹細胞
WO2012041867A2 (en) 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
WO2012071513A2 (en) 2010-11-24 2012-05-31 Hong Gao Expanding hematopoietic stem cells
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
EP3332804A1 (de) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvanzien auf listerien-basis
DK3205353T3 (da) 2011-03-21 2021-04-06 Altimmune Inc Hurtig- og langtidsvirkende immunologisk terapeutisk middel
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US9725490B2 (en) 2011-07-29 2017-08-08 Tokushima University ERAP1-derived peptide and use thereof
RU2612905C2 (ru) 2011-08-12 2017-03-13 Онкотерапи Сайенс, Инк. Пептиды mphosph1 и вакцины, включающие их
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
JP2014527818A (ja) 2011-09-16 2014-10-23 フェイト セラピューティクス，インコーポレイテッド Ｗｎｔ組成物およびそのような組成物の治療的使用
TWI571513B (zh) 2011-09-28 2017-02-21 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
CA2852633C (en) 2011-10-28 2021-08-03 Oncotherapy Science, Inc. Topk peptides and vaccines including the same
CN103239734B (zh) 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
US9561265B2 (en) 2012-07-10 2017-02-07 Oncotherapy Science, Inc. KIF20A epitope peptides for TH1 cells and vaccines containing the same
SG10201701866QA (en) 2012-09-11 2017-04-27 Oncotherapy Science Inc Ube2t peptides and vaccines containing the same
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
KR102258021B1 (ko) 2012-12-13 2021-06-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｗｔ１ 백신
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US9592303B2 (en) 2013-05-30 2017-03-14 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
WO2015054012A1 (en) 2013-10-07 2015-04-16 The Trustees Of The University Of Pennsylvania Vaccines with interleukin-33 as an adjuvant
US10370664B2 (en) 2013-11-07 2019-08-06 University Of Southern California Use of IKK epsilon inhibitors to activate NFAT and T cell response
CA2930695C (en) 2013-11-14 2024-05-14 Inovio Pharmaceuticals, Inc. Hiv-1 env dna vaccine plus protein boost
CN112057613A (zh) 2013-11-29 2020-12-11 宾夕法尼亚大学理事会 MERS-CoV疫苗
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
IL250235B (en) 2014-08-04 2022-07-01 Oncotherapy Science Inc A peptide derived from urlc10 and a component containing it
US10676514B2 (en) 2014-08-04 2020-06-09 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same
CN111925414A (zh) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
US10166288B2 (en) 2014-10-01 2019-01-01 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US10806773B2 (en) 2014-10-09 2020-10-20 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
EP3229810B1 (de) 2014-11-17 2020-07-22 Cellectar Biosciences, Inc. Phospholipidetheranaloga als auf krebs abzielende arzneimittelträger
EP3242883A4 (de) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid-a-mimetika, verfahren zur herstellung und verwendungen davon
ES2929532T3 (es) 2015-01-29 2022-11-30 Univ Pennsylvania Combinaciones de inhibidores de puntos de control y vacunas y su uso en inmunoterapia
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
EP3393500B1 (de) 2015-12-21 2021-10-13 Duke University Polymerkonjugate mit verringerter antigenizität
US20210309965A1 (en) 2016-03-21 2021-10-07 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US20190284263A1 (en) 2016-04-29 2019-09-19 Inovio Pharmaceuticals, Inc. In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
WO2018057618A1 (en) 2016-09-20 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
EP3541378A4 (de) 2016-11-16 2020-10-07 University of South Florida Allosterische antagonisten von gprc6a und deren verwendung bei der linderung von proteinopathien
US10376495B2 (en) 2016-11-23 2019-08-13 University Of South Florida Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)
WO2018129040A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US10813935B2 (en) 2017-02-23 2020-10-27 Transgenex Nanobiotech, Inc. Methods and compositions for treating drug resistance in cancer
US10272052B2 (en) 2017-02-24 2019-04-30 University Of South Florida Compositions and methods for the treatment of tauopathies
US11318155B2 (en) 2017-02-24 2022-05-03 University Of South Florida Hsp90 activator Aha1 drives production of pathological tau aggregates
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3634496A4 (de) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. Verfahren zur sensibilisierung von krebszellen gegen t-zell-vermittelte abtötung mittels modulierung von molekularen signalwegen
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
US11980671B2 (en) 2017-07-26 2024-05-14 Duke University Use of bacterial voltage gated ion channels for human therapies
US11306059B2 (en) 2017-10-25 2022-04-19 University Of South Florida Drug-induced activation of the Reelin signaling system
EP3720508A4 (de) 2017-12-08 2021-09-01 University of Connecticut Zusammensetzungen und verfahren zur behandlung genetischer prägungsstörungen
US11254704B2 (en) 2018-01-05 2022-02-22 University Of South Florida Compounds and methods for reducing or inhibiting aggregation of proteins in a subject
CA3087418A1 (en) 2018-01-18 2019-07-25 University Of South Florida Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases
US11491206B1 (en) 2018-02-13 2022-11-08 Duke University Compositions and methods for the treatment of trail-resistant cancer
US20200407700A1 (en) 2018-02-26 2020-12-31 President And Fellows Of Harvard College Compositions of parp14 modulators and/or mutants and therapeutic use thereof
US20210162007A1 (en) 2018-04-09 2021-06-03 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
EP3829622A4 (de) 2018-08-02 2022-05-11 Duke University Doppel-agonisten-fusionsproteine
WO2020111167A1 (ja) 2018-11-30 2020-06-04 国立大学法人徳島大学 Ｂｉｇ３－ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬
EP3962529A4 (de) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
BR112022006739B1 (pt) 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
EP4110468A1 (de) 2020-02-25 2023-01-04 Inovio Pharmaceuticals, Inc. Impfstoffe gegen coronavirus und verfahren zur verwendung
MX2022014248A (es) 2020-05-14 2022-12-02 Inovio Pharmaceuticals Inc Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas.
US20230272378A1 (en) 2020-06-12 2023-08-31 University Of Rochester ENCODING AND EXPRESSION OF ACE-tRNAs
US20230374599A1 (en) 2020-10-19 2023-11-23 Alexander Gusev Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
US20240024474A1 (en) 2020-11-13 2024-01-25 David Avigan Personalized fusion cell vaccines
US20240158864A1 (en) 2021-01-25 2024-05-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
WO2022178438A1 (en) 2021-02-22 2022-08-25 Duke University Non-immunogenic poegma-aptamer conjugates
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023004332A2 (en) 2021-07-19 2023-01-26 New York University Adeno-associated viral vector compositions and methods of promoting muscle regeneration
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2024011033A1 (en) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogens and methods for inducing an immune response
WO2024102187A1 (en) 2022-11-07 2024-05-16 Pinetree Therapeutics, Inc. Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3596660A (en) * 1969-05-12 1971-08-03 Illinois Tool Works Injection device
DE69032284T2 (de) * 1989-03-21 1998-10-08 Vical, Inc., San Diego, Calif. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery

Also Published As

Publication number Publication date
AU4198196A (en) 1996-05-31
EP0789574B1 (de) 2006-04-19
DE69534946D1 (de) 2006-05-24
US5679647A (en) 1997-10-21
JPH10509702A (ja) 1998-09-22
CA2203991C (en) 2002-08-20
CA2203991A1 (en) 1996-05-17
DE69534946T2 (de) 2006-12-28
EP0789574A4 (de) 2001-08-29
EP0789574A1 (de) 1997-08-20
WO1996014074A1 (en) 1996-05-17

Similar Documents

Publication Publication Date Title
ATE323496T1 (de) Verwendung von nackten polynukleotiden zur herstellung eines medikaments für die behandlung von tumoren
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
EP0794797A4 (de) Methoden und zubehör zur immunisierung von wirtsorganismen durch verabreichung nackter polynucleotide , welche für antigene peptide codieren
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DE69433590D1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
US6338853B1 (en) Anti-cancer vaccine
DE19602985A1 (de) Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
DE60036105D1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
US5993829A (en) Anti-cancer vaccine
EP1961819A3 (de) Zusammensetzungen und Verfahren zur Heilung und Diagnose von Lungenkrebs
Baltz Vaccines in the treatment of cancer
DE60139150D1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties